AARTI PHARMALABS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 602.4 INR | +2.48% |
|
+7.18% | +19.41% |
| May. 14 | GRIFOLS SHARES DOWN 4.8% AFTER GOTHAM CITY RESEARCH ISSUES REPOR… | RE |
| May. 13 | Aarti Pharmalabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024 | CI |
| Sales 2022 | 12K 1M | Sales 2023 | 19.45K 1.62M | Capitalization | 25B 2,087B |
|---|---|---|---|---|---|
| Net income 2022 | 1.22B 102B | Net income 2023 | 1.94B 162B | EV / Sales 2022 * | - |
| Net Debt 2022 | 2.58B 216B | Net Debt 2023 | 1.52B 127B | EV / Sales 2023 | 1,363,395 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
12.9
x | Employees | 2,042 |
| Yield 2022 * |
-
| Yield 2023 |
0.73% | Free-Float | 52.07% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.48% | ||
| 1 week | +7.18% | ||
| Current month | +7.18% | ||
| 1 month | +17.33% | ||
| 3 months | +32.12% | ||
| 6 months | +27.40% | ||
| Current year | +19.41% |
1 week
497.05
608.85
1 month
487.85638.75
Current year
399.55638.75
1 year
320.30638.75
3 years
234.80638.75
5 years
234.80638.75
10 years
234.80638.75
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 59 | 22-10-16 | |
Hetal Gogri Gala
CEO | Chief Executive Officer | 48 | 22-10-16 |
Piyush Lakhani
DFI | Director of Finance/CFO | - | 22-10-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hetal Gogri Gala
CEO | Chief Executive Officer | 48 | 22-10-16 |
| Chairman | 50 | 21-08-06 | |
| Director/Board Member | 77 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 602.4 | +2.48% | 215,279 |
| 24-06-06 | 587.8 | +1.80% | 155,498 |
| 24-06-05 | 577.4 | +6.59% | 305,919 |
| 24-06-04 | 541.6 | -5.87% | 373,308 |
| 24-06-03 | 575.4 | +2.39% | 252,180 |
Delayed Quote NSE India S.E., June 07, 2024 at 07:58 am EDT
More quotes
Aarti Pharmalabs Limited is a manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), xanthine derivatives, and allied products, situated in India. The Company delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, and others. Its Caffeine products include caffeine anhydrous, and caffeine anhydrous (granules).
Sector
Pharmaceuticals
Calendar
2024-08-04
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +19.41% | 654M | |
| +45.82% | 765B | |
| +40.95% | 632B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| +11.88% | 216B | |
| -0.78% | 219B | |
| +5.90% | 164B |
- Stock Market
- Equities
- AARTIPHARM Stock
